Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 25, Issue 23, Pages 2839-2845
Publisher
Baishideng Publishing Group Inc.
Online
2019-06-19
DOI
10.3748/wjg.v25.i23.2839
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies
- (2019) Manish R. Sharma et al. CANCER
- Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma
- (2019) Takahiro Akahori et al. ONCOLOGIST
- Drain Contamination after Distal Pancreatectomy: Incidence, Risk Factors, and Association with Postoperative Pancreatic Fistula
- (2019) Feng Yang et al. JOURNAL OF GASTROINTESTINAL SURGERY
- NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
- (2019) Andrea Wang-Gillam et al. EUROPEAN JOURNAL OF CANCER
- Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
- (2019) Mark J. Truty et al. ANNALS OF SURGERY
- Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
- (2018) Jihoon Kang et al. INVESTIGATIONAL NEW DRUGS
- Impact of UGT 1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX
- (2018) Hiromichi Shirasu et al. CANCER SCIENCE
- Clinical significance of drain fluid culture after pancreaticoduodenectomy
- (2018) Feng Yang et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Neoadjuvant and adjuvant chemotherapy in pancreatic cancer
- (2018) Ulla Klaiber et al. LANGENBECKS ARCHIVES OF SURGERY
- A Glimmer of Hope for Pancreatic Cancer
- (2018) Hedy L. Kindler NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe
- (2018) Muhammad Ahsan Javed et al. PANCREATOLOGY
- Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis
- (2017) Ali A. Mokdad et al. JOURNAL OF CLINICAL ONCOLOGY
- CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
- (2017) Marianne Sinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma
- (2017) Yang Chen et al. Scientific Reports
- Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX
- (2017) Theodoros Michelakos et al. ANNALS OF SURGERY
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
- (2016) Katsuhiko Uesaka et al. LANCET
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib
- (2016) Jae Min Lee et al. World Journal of Gastrointestinal Oncology
- More Accurate Prediction of Metastatic Pancreatic Cancer Patients’ Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity
- (2016) Younak Choi et al. PLoS One
- Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma
- (2015) Hiroaki Yanagimoto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets
- (2015) Riccardo Casadei et al. JOURNAL OF GASTROINTESTINAL SURGERY
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection
- (2015) Yoshihiro Shirai et al. SURGERY
- Current status and progress of pancreatic cancer in China
- (2015) Quan-Jun Lin WORLD JOURNAL OF GASTROENTEROLOGY
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy
- (2014) Guopei Luo et al. ANNALS OF SURGICAL ONCOLOGY
- Impact of Tumor Grade on Pancreatic Cancer Prognosis: Validation of a Novel TNMG Staging System
- (2013) Matthew M. Rochefort et al. ANNALS OF SURGICAL ONCOLOGY
- Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery
- (2013) Fuyuhiko Motoi et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis
- (2013) Wei-Chih Liao et al. LANCET ONCOLOGY
- Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment
- (2012) Feng Yang et al. CANCER TREATMENT REVIEWS
- Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
- (2012) Katia T. Papalezova et al. JOURNAL OF SURGICAL ONCOLOGY
- Liposome based delivery systems in pancreatic cancer treatment: From bench to bedside
- (2011) Feng Yang et al. CANCER TREATMENT REVIEWS
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- (2010) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started